Fig. 2: KRAS KO tumors fail to evade host immune system.
From: KRAS drives immune evasion in a genetic model of pancreatic cancer
a Orthotopic pancreatic tumor in wild-type C57BL/6 mice derived from KRAS KO KPC cells. Normal pancreas is shown on left (control). b Bar graphs showing the quantification of wild-type mice with tumors formed by KRAS intact and KRAS KO KPC cells and the respective tumor latencies (n = 86 individual mice). Data are expressed as mean ± SD. Significance was determined using Fisher’s exact test (left panels) or two-tailed t-test at the 0.05 confidence interval (right panels). c Histological appearance of orthotopic tumors arising from KRAS intact and KRAS KO KPC cells. Scale bar 600 μM. d Bar graphs display the quantification of mice with metastatic foci. e Quantification of tumor-initiating cells (TIC) in KRAS intact and KRAS KO KPC cells in wild-type mice. f IHC staining of tumors shown in (c) with antibodies noted. Areas of necrosis (NEC) are present in KRAS KO but not KRAS intact KPC tumors. Scale bar 100 μM. g Bar graph showing the quantification of tumor-infiltrating immune cells in KRAS intact and KRAS KO KPC tumors (n = 3 independent experiments). Relative cell number per 10 high power fields is shown. Individual points represent separate high power fields. Data are presented as mean ± SD, two-tailed t-test.
